For Immediate Release
Contact: Lisa Finger, 919-933-2021, lfinger@biosignia.com
BioSignia, Inc. Announces Research Agreement with Aurigen
Reinsurance Company
Sponsored Research Project to Explore Cognitive Function as
Indicator of Mortality Risk
Research Triangle Park, North Carolina – October 10, 2011
— BioSignia, a predictive modeling company providing innovative
solutions for the healthcare and life insurance industries, today
announced the signing of a sponsored research agreement with Aurigen
Reinsurance Company (“Aurigen”), a life and health reinsurance
company in Canada. BioSignia will conduct research under a
three-month contract with Aurigen that will investigate correlations
between cognitive function and mortality.
BioSignia’s Chief Scientific Officer, Dr. Guizhou Hu, will serve as
lead investigator on the project. “Cognitive function has been found
to be inversely associated with subsequent mortality in elderly
adults in several clinical studies,” said Dr. Hu. “In our research
efforts with Aurigen we hope to further expand the understanding of
specific cognitive function measures as an indicator of mortality
risk for both elderly and middle-aged populations.”
“Aurigen is excited to collaborate with Dr. Hu and the staff at
BioSignia to further our knowledge in mortality risk assessment,”
said Bob Brown, Chief Pricing Officer with Aurigen.
For more information on BioSignia’s research or market applications,
please call 888.324.6627 or email
info@biosignia.com.
# # #
About BioSignia
Headquartered in Research Triangle Park, N.C., BioSignia is a
leading technology company focused on bringing innovative predictive
modeling solutions to the life insurance and preventive healthcare
markets. BioSignia’s patented technology, Synthesis Analysis™,
provides the underpinnings of BioSignia’s life insurance
application, Mortality Assessment Technology™ (MAT). This modeling
capability represents a quantum leap forward in both morbidity and
mortality risk assessment. In 2004, BioSignia received the award for
Best Enabling Tool for Disease Management from DMAA: The Care
Continuum Alliance. Since then, BioSignia’s talented R&D team has
continued to advance synthesis modeling, continuously updating it to
reflect the ever expanding need for better risk assessment as well
as effective chronic disease prevention, management and treatment.
For more information about BioSignia, visit:
www.biosignia.com.
About Aurigen Reinsurance Company
Aurigen’s core business is the reinsurance of individual life
insurance policies. It has 38 employees and is currently licensed to
transact life reinsurance in Canada and Bermuda. Aurigen’s operating
life reinsurance companies each have financial strength ratings of
A- (Excellent) from A.M. Best, life reinsurance in force in excess
of CAD $20 billion and consolidated assets in excess of CAD $250
million.
|
|
|
